Selective Serotonin Reuptake Inhibitors: Packaging
The question
To ask the Secretary of State for Health and Social Care, pursuant to the answer of 4 July 2025 to question 63299, when he plans to publish the report on packaging changes to Selective serotonin reuptake inhibitors, as discussed at the Commission on Human Medicines Antidepressant Risk Minimisation Expert Working Group on 1 May.
Answered by Dr Zubir Ahmed
The Commission on Human Medicines Antidepressant Risk Minimisation Expert Working Group met in May and July 2025 and their recommendations were subsequently considered by the Commission on Human Medicines in September 2025.
A public assessment report summarising the data considered and the recommendations will be published by the Medicines and Healthcare products Regulatory Agency (MHRA) as soon as the regulatory position is finalised with the 105 marketing authorisation holders of the 28 antidepressants involved in the review. An exact date for publication of the public assessment report cannot be confirmed yet.
The MHRA will issue a Drug Safety Update to inform healthcare professionals in the United Kingdom of the new regulatory position for all antidepressants, not only selective serotonin reuptake inhibitors, and publication of the public assessment report.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →